抗坏血酸棕榈酸酯

人体单次局部应用后未观察到皮肤刺激，证实抗坏血酸棕榈酸酯在该条件下无刺激风险

No skin irritation observed after single topical application in humans, confirming ascorbyl palmitate has no irritation risk under these conditions

含10%抗坏血酸的产品在人体最大化试验中未引起接触致敏，且含5%抗坏血酸的乳膏在103名受试者中未诱导皮肤致敏。

A product containing 10% Ascorbic Acid was not a contact sensitizer in a maximization assay on 26 humans, and an opaque cream containing 5% Ascorbic Acid did not induce dermal sensitization in 103 human subjects.

小鼠和大鼠口服抗坏血酸高达1000 mg/kg bw/天未见母体毒性、致畸性或胎儿毒性，且该成分在化妆品中外用浓度低，透皮吸收有限，无孕期风险证据。

Oral doses up to 1000 mg/kg bw/day in pregnant mice and rats showed no maternal, teratogenic, or fetotoxic effects; cosmetic use involves low topical concentrations with limited percutaneous absorption, no evidence of pregnancy risk.

AP作为limosomes组分，研究显示高生物相容性和光保护作用，未发现风险。

AP as limosome component, study shows high biocompatibility and photoprotection, no risk found.

AP作为纳米粒组分，研究显示无刺激性，且具有光保护作用，未发现风险。

AP as nanoparticle component, study shows no irritation and photoprotective effect, no risk found.

AP作为aspasomes的组分，研究未提及AP的刺激或致敏风险，且制剂在临床中安全有效。

AP as component of aspasomes, no mention of AP irritation or sensitization risk, and formulation safe and effective in clinic.

AP作为抗氧化剂辅助稳定视黄醇棕榈酸酯，未研究AP本身的皮肤风险。

AP used as antioxidant to stabilize retinyl palmitate, no study on AP's own skin risk.

AP作为对照化合物用于酶解比较，未涉及皮肤刺激或致敏。

AP used as control for enzymatic hydrolysis comparison, no skin irritation or sensitization involved.

研究显示AP具有保湿效果，未提及皮肤刺激或致敏风险，且AP作为活性成分被安全使用。

The study shows AP has moisturizing effect, no mention of skin irritation or sensitization risk, and AP is safely used as active ingredient.

AP作为对照化合物，研究其皮肤渗透和滞留，未提及任何刺激或致敏风险。

AP used as control compound for skin penetration and retention, no mention of irritation or sensitization risk.

AP作为抗氧化剂研究，未涉及皮肤刺激或致敏，且通过人体表皮渗透，无风险证据。

AP studied as antioxidant, no skin irritation or sensitization involved, and permeated through human epidermis without risk evidence.